Lantheus Holdings (LNTH) Peer Comparison
$102.10
As on 19-Nov-2026 14:31EST
Market cap
$6,644 Mln
Revenue (TTM)
$1,562 Mln
P/E Ratio
25.3
P/B Ratio
4.9
Div. Yield
0 %
| Lantheus Holdings (LNTH) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
6,644 | 14,620 | 12,647 | 10,726 | 10,488 |
Revenue ($ Mln) |
1,562 | 690 | 1,560 | 806 | 2,593 |
Net Profit ($ Mln) |
269.91 | -169.80 | 157.02 | -11.80 | 1,022.90 |
Net Margin (%) |
17.28 | -24.60 | 10.06 | -1.47 | 39.45 |
RoE (%) |
21.02 | -24.46 | 10.27 | -0.56 | 14.15 |
Price to Earnings |
25.27 | -- | 80.82 | -- | 10.36 |
Price-To-Book |
4.88 | 20.40 | 7.98 | 5.09 | 1.38 |
Income Statement ($ Mln)
| Lantheus Holdings (LNTH) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,562.21 | 690.33 | 1,560.33 | 805.61 | 2,592.70 |
|
Cost of Revenue
|
605.15 | 130.29 | 499.55 | 394.34 | 1,263.70 |
|
Gross Profit
|
941.95 | 393.22 | 942.44 | 347.62 | 1,343.60 |
|
Operating Expenses
|
666.13 | 623.34 | 871.54 | 392.34 | 1,209.10 |
|
Operating Profit (EBIT)
|
290.93 | -63.30 | 189.25 | 18.93 | 118.90 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
342.37 | -174.52 | 207.82 | 8.23 | 1,320.20 |
|
Provision for Tax
|
72.47 | -4.72 | 50.81 | 20.03 | 297.30 |
|
Profit after Tax (Net Income)
|
269.91 | -169.80 | 157.02 | -11.80 | 1,022.90 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 47.34 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Lantheus Holdings (LNTH) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,355.71 | 717.27 | 1,583.51 | 2,091.74 | 7,603.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
754.45 | 135.53 | 207.78 | 708.99 | 2,211.00 |
|
Current Liabilities
|
345.97 | 126.73 | 233.81 | 125.69 | 969.10 |
|
Total Liabilities
|
2,227.40 | 893.49 | 1,826.52 | 2,949.70 | 10,576.50 |
Assets ($ Mln)
| Lantheus Holdings (LNTH) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,332.42 | 399.88 | 648.47 | 1,684.42 | 7,704.50 |
|
Current Assets
|
1,123.71 | 579.65 | 1,376.63 | 1,241.98 | 3,078.60 |
|
Total Assets
|
2,227.40 | 893.49 | 1,826.52 | 2,949.70 | 10,576.50 |
|
Total Debt*
|
54.05 | 101.98 | 209.39 | 692.24 | 1,363.40 |
|
Net Current Assets
|
777.74 | 452.92 | 1,142.82 | 1,116.30 | 2,109.50 |
Cashflow ($ Mln)
| Lantheus Holdings (LNTH) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
390.14 | -46.34 | 238.66 | 117.42 | 532.20 |
|
Cash Flow from Investing Activities
|
-627.17 | -77.61 | -404.59 | -298.47 | -189.70 |
|
Cash from Financing Activities
|
-316.58 | 11.89 | 26.53 | -15.21 | -283.20 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Lantheus Holdings (LNTH) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
ROCE (%)
|
13.67 | -22.53 | 11.76 | 1.79 | 8.98 |
|
ROE (%)
|
21.02 | -24.46 | 10.27 | -0.56 | 14.15 |
|
ROA (%)
|
9.95 | -15.48 | 7.53 | -0.39 | 9.31 |
|
EBIT Margin (%)
|
23.18 | -24.51 | 13.40 | 4.20 | 52.80 |
|
Net Margin (%)
|
17.28 | -24.60 | 10.06 | -1.47 | 39.45 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Lantheus Holdings (LNTH) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
2.38 | 46.94 | 16.98 | 13.80 | 1.38 |
|
EBIT Growth (%)
|
38.04 | -106.70 | 11.72 | 29.47 | 272.53 |
|
Net Profit Growth (%)
|
60.96 | -93.80 | -4.27 | -779.17 | 251.34 |
|
EPS Growth (%)
|
70.28 | -90.00 | -4.95 | -910.66 | 256.24 |
|
Book Value Growth (%)
|
19.80 | -12.58 | 15.61 | 0.35 | 12.77 |
Valuation Ratios
| Lantheus Holdings (LNTH) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Price / Earnings
|
18.90 | -34.59 | 68.93 | 189.42 | -- |
|
Price / Book Value
|
4.05 | 9.90 | 8.58 | 4.40 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
11.58 | -43.50 | 53.25 | 50.32 | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Lantheus Holdings (LNTH) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.42 | 0.00 | 0.00 | 0.27 | 0.11 |
|
Short term debt to equity ratio
|
0.00 | 0.00 | 0.01 | 0.01 | 0.06 |
|
Current Ratio
|
3.25 | 4.57 | 5.89 | 9.88 | 3.18 |
|
Quick Ratio
|
3.06 | 4.09 | 3.92 | 8.43 | 2.37 |
|
Interest Coverage
|
18.29 | -35.23 | 165.16 | 1.24 | 28.05 |
Operating Efficiency Ratios
| Lantheus Holdings (LNTH) | Glaukos Corp (GKOS) | Penumbra (PEN) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
22.13 | 21.73 | 12.51 | 18.77 | 16.30 |
|
Asset Turnover
|
0.58 | 0.63 | 0.75 | 0.26 | 0.24 |
|
Receivable days
|
80.54 | 60.95 | 46.54 | 72.41 | 65.39 |
|
Inventory Days
|
40.41 | 193.84 | 331.92 | 146.53 | 221.09 |
|
Payable days
|
23.59 | 60.19 | 26.16 | 29.05 | 37.02 |
|
Cash Conversion Cycle
|
97.36 | 194.60 | 352.30 | 189.88 | 249.46 |